A groundbreaking study led by UCLA Health, recently published in the prestigious journal Cell, marks a pivotal advancement in the realm of personalized medicine. This research leverages a uniquely diverse biobank—the UCLA ATLAS Community Health Initiative Biobank—containing genetic and clinical data from nearly 94,000 participants representing a myriad of ancestries. By analyzing both genomic information and electronic health records from this clinically well-characterized population, researchers have uncovered novel genetic determinants that influence disease risk and therapeutic responses, shedding light on complexities previously obscured by less diverse datasets.
Central to this study is the demonstration that genetic ancestry profoundly impacts how patients respond to therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly prescribed for weight loss and type 2 diabetes. The researchers found that therapeutic efficacy of GLP-1 drugs, such as semaglutide, varies significantly across different ancestral populations, and critically, this variability correlates with individuals’ genetic risk scores for type 2 diabetes. Such findings underscore the limitations of one-size-fits-all treatment approaches and herald a new era where genetic insights inform tailored medical interventions.
Utilizing integrative proteogenomic analyses, the team pinpointed a key genetic association between response to semaglutide and the gene PTPRU. This gene had not previously been linked to GLP-1 drug response, offering compelling evidence for its role in modulating treatment outcomes. Proteomics data from patients undergoing GLP-1 therapy further reinforced these findings, providing a molecular bridge between genotypic variation and phenotypic drug responsiveness. This discovery paves the way for future mechanistic studies and the potential development of predictive biomarkers to optimize obesity and diabetes therapies.
The ATLAS Biobank uniquely encompasses an expansive representation of ancestries, reflecting Los Angeles’ unparalleled ethnic diversity. Participants hail from five continental ancestries and encompass thirty-six fine-scale ancestry groups, including communities historically underrepresented in genetic research such as Armenian, Ashkenazi Jews, Iranian Jewish, Filipino, and Mexican American populations. This breadth allows for the disentanglement of genetic influences on health outcomes without confounding by healthcare system disparities, a common challenge when comparing data across institutions.
Historically, the majority of genomic studies have disproportionately sampled populations of European descent, limiting the applicability of findings to the global population and exacerbating health disparities. The UCLA ATLAS initiative confronts this bias head-on by drawing from one of the world’s most ancestrally diverse metropolitan areas—Los Angeles County—which boasts over 9.6 million residents. By integrating diverse genetic data with longitudinal clinical records within a single health system, this study establishes a paradigm for equitable precision medicine research.
Beyond common genetic variants, the study pioneers examination of rare variants within specific ancestry groups, unveiling hitherto unknown genetic correlations with disease phenotypes. For instance, the gene ANKZF1 was linked to peripheral vascular disease among African ancestry individuals, while EPG5 was associated with lipid metabolism traits such as HDL cholesterol and triglyceride levels in Ashkenazi Jewish participants. These discoveries highlight the importance of including rare variant analyses in multi-ancestry cohorts to illuminate genetic contributions to complex diseases.
The investigation also delineated ancestry-specific susceptibilities to adverse drug reactions. Among Mexicans and South Americans, increased vulnerability to negative hormonal therapy effects was observed, reinforcing the need for ancestry-informed pharmacovigilance. This awareness is critical for improving drug safety profiles and optimizing treatment plans for diverse populations, thereby enhancing patient outcomes and reducing health inequities.
A further significant dimension of the research involves polygenic risk scores (PRS), composite metrics summarizing genetic predispositions to diseases based on numerous variants spread across the genome. Within the ATLAS cohort, PRS demonstrated promising predictive power for conditions like type 1 diabetes, with a substantial proportion of patients exhibiting elevated scores matching their clinical diagnoses. Though clinical translation remains in early stages, these findings position PRS as a valuable tool for stratifying patient risk and guiding preventive strategies.
The researchers’ focus on GLP-1 receptor agonists as a case study showcases how genetic diversity can influence response to commonly prescribed medications. GLP-1 drugs, including branded agents such as Ozempic and Wegovy, have revolutionized treatment for obesity and diabetes but exhibit variable efficacy among individuals. Identifying genetic markers like those in PTPRU provides a molecular rationale for this heterogeneity and suggests pathways to develop predictive algorithms to personalize therapy.
Importantly, the UCLA Health system’s comprehensive real-world data environment—linking genetics with electronic health records—affords robust insights into disease pathogenesis and therapeutic outcomes within a clinical context. This approach contrasts with isolated laboratory investigations, elevating the translational potential of discoveries. As Dr. Daniel Geschwind, senior associate dean of Precision Health at UCLA, notes, ATLAS’s integration of broad and fine-scale ancestries illuminates genetic factors overlooked in earlier studies focused on broad ancestral categories alone.
Already, the ATLAS Biobank supports a public web portal presenting thousands of heritable genetic associations across diverse populations, enabling researchers worldwide to access and build upon these unprecedented data. With over 259,000 participants consented and 157,000 biospecimens collected since its launch in 2016, this initiative embodies a scalable model for genomic medicine research embedded within large health systems, fostering health equity by design.
The implications of these findings extend far beyond the academic sphere. They propel precision medicine closer to practical application, where individual genomic profiles guide risk assessment, diagnosis, and personalized treatments. Furthermore, this study is a call to action emphasizing the necessity of inclusive genetic research that respects and reflects population diversity to fulfill the promise of equitable, effective healthcare for all.
In conclusion, the UCLA Health-led study published in Cell underscores the transformative impact of integrating genetic diversity, clinical data, and molecular biology within a single health ecosystem. It highlights novel genetic determinants influencing disease risk and drug response, particularly in relation to type 2 diabetes and weight loss medications. By bridging gaps in ancestry representation and leveraging comprehensive real-world data, the work sets a new standard for precision health discovery and clinical translation, demonstrating that personalized medicine is not just a possibility for some but an achievable goal for the global population.
Subject of Research: Human tissue samples
Article Title: Advancing Precision Health Discovery in a Genetically Diverse Health System
News Publication Date: 27-Mar-2026
Web References: [UCLA ATLAS Community Health Initiative Biobank Web Portal] (link not provided in source)
References: DOI: 10.1016/j.cell.2026.03.007
Keywords: precision medicine, genetic diversity, GLP-1 receptor agonists, type 2 diabetes, polygenic risk scores, ancestry, genetic associations, semaglutide, pharmacogenomics, health disparities, rare genetic variants, proteomics
